Stoke Therapeutics Files 8-K
Ticker: STOK · Form: 8-K · Filed: Jul 10, 2025 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-disclosure
TL;DR
Stoke Therapeutics filed an 8-K on 7/10/25 for regulatory and financial disclosures.
AI Summary
On July 10, 2025, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates Stoke Therapeutics is making a regulatory disclosure and submitting financial exhibits, which is standard procedure for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material event or risk.
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- July 10, 2025 (date) — Date of Report
- 45 Wiggins Ave, Bedford, Massachusetts 01730 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Stoke Therapeutics, Inc.?
The filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was this 8-K report filed?
The report was filed on July 10, 2025.
What is the principal executive office address for Stoke Therapeutics, Inc.?
The address is 45 Wiggins Ave, Bedford, Massachusetts 01730.
What is the Commission File Number for Stoke Therapeutics, Inc.?
The Commission File Number is 001-38938.
What is the IRS Employer Identification No. for Stoke Therapeutics, Inc.?
The IRS Employer Identification No. is 47-1144582.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 10, 2025 regarding Stoke Therapeutics, Inc. (STOK).